

Assessing the barriers to prescribing biologic therapies among prurigo nodularis patients

Amber King¹, Georgia Giannakopoulou¹, Hannah Brown¹, Hamizah Hamdan², Atikah Kamaruddin²
¹Ipsos, London, United Kingdom ²Ipsos, Kuala Lumpur, Malaysia

Introduction

Biologic treatment has recently been approved for prurigo nodularis (PN), offering potential¹ in an indication with otherwise limited options.

Objective

The objective of this study was to explore barriers to biologic prescribing in PN, and factors for discerning patient eligibility for a biologic.

Methods

The Ipsos PN Therapy Monitor, an ongoing multi-center online medical chart review study of patients with PN was conducted between November – December 2022 among 70 dermatologists from the USA. Physicians were screened for practice duration, patient volume and ability to prescribe advanced therapies. Charts of patients with PN were included in the analysis.

Conclusions

Comparisons in this study cohort suggest biologic treatment is initially being considered for PN patients with a greater disease burden. Patient decision has the potential to limit initial uptake, along with insurance coverage, although further investigation is warranted.

CONTACT US: TherapyMonitors@ipsos.com

www.ipsos.com

© Ipsos 2024, all rights reserved.

HCPs in our study cite disease severity parameters and patient refusal when assessing biologic eligibility and prescription to treat prurigo nodularis



Scan the code to download poster and full abstract

E-Poster # 53063
AAD 2024, San Diego, 8-11 March

Figure 1A: Physician perceptions of eligibility for a biologic treatment, among reported PN patients not currently biologic treated




Figure 1B: Recorded clinical characteristics of reported PN patients




Figure 2A: Physician stated barriers to prescribing a biologic





Figure 2B: Physician perceptions of reason(s) why reported biologic eligible PN patients are not biologic treated



Source for all charts: Ipsos PN Therapy Monitor (US HCPs providing de-identified patient record data on PN patients seen in consultation & perceptions online. See 'Methods' for full details). Data are © Ipsos 2024, all rights reserved.

REFERENCES

[1] Svenja Müller, Thomas Bieber & Sonja Ständer (2022). 'Therapeutic potential of biologics in prurigo nodularis', Expert Opinion on Biological Therapy, vol 22(1), pp 47-58.